An NCORP Hat Trick: Three Primary Results Papers Published
Three SWOG NCORP Research Base studies – S1714, S1904, and S1600 – have reported primary results in manuscripts published over the last few months.
S1714
Led by Dr. Meghna S. Trivedi, S1714 was a prospective observational cohort study of patients with early-stage cancer who were starting treatment with taxane-based chemotherapy. The study’s primary objective was to develop a risk prediction model that could be used to estimate a given patient’s risk of developing taxane-induced peripheral neuropathy (TIPN), a side effect that impacts quality of life and often leads to early discontinuation of treatment.
The study enrolled 1,278 evaluable patients, 804 of whom (62.9 percent) would experience TIPN by week 24 of their treatment.
From the collected data, the S1714 team derived and validated a model that associates five clinical factors with an increased risk of TIPN:
- treatment with paclitaxel (versus docetaxel)
- stage II or III disease (versus stage I)
- planned taxane treatment duration of more than 12 weeks
- a baseline diagnosis of diabetes, autoimmune disease, moderate kidney disease, or a neurologic condition
- self-reported Black, Native American, Pacific Islander, multiple, or unknown race or Hispanic ethnicity (versus White or Asian race)
Patients with three to five of these clinical factors had a TIPN risk that was almost five times greater than the TIPN risk for those with none of these factors.
The S1714 risk model can be easily applied in the clinic, where it could help guide treatment decisions when other treatment options are available and could inform decisions about monitoring patients for TIPN symptoms.
(Trivedi MS, JAMA Netw Open 2026)
S1904 (MiCHOICE)
Among women at high risk for breast cancer, chemoprevention with aromatase inhibitors or selective estrogen receptor modulators can substantially reduce breast cancer incidence, but uptake of chemoprevention is low.
The S1904 MiCHOICE study, led by Dr. Katherine D. Crew, tested whether adding specially developed web-based decision support tools to standard educational materials – for both patients and providers – could help more of these women with high-risk breast lesions make informed decisions about chemoprevention.
A cluster-randomized trial, S1904 enrolled 412 patients and 210 clinicians. The primary outcome measured was informed choice about chemoprevention at six months, defined as having adequate knowledge of chemoprevention and attitudes consistent with a chemoprevention intention or decision.
The study team did not see a statistically significant increase in informed choice among those on the chemoprevention decision support arm as compared to those getting standard educational materials alone. Patients on the intervention arm, however, were more likely to have accurate perceptions of breast cancer risk and adequate chemoprevention knowledge.
Importantly, the percentage of women on both arms who decided to start chemoprevention was substantially higher than what’s been seen historically, suggesting that simply participating in the study may have made it more likely women would begin chemoprevention.
(Crew KD, JNCI 2026)
S1600
Radical cystectomy for bladder cancer is associated with high rates of complications. The randomized, double-blind S1600 study, led by Dr. Jill Hamilton-Reeves, asked whether specialized immunonutrition (SIM) taken perioperatively could reduce the rates of postoperative complications in these patients.
The trial enrolled 203 patients with bladder carcinoma (178 of whom were evaluable) who drank either a standard oral nutrition support drink or the SIM drink (fortified with L-arginine, omega-3 fatty acids, and dietary nucleotides) three times daily for five days before and for five days after surgery.
The study team saw no significant differences between the arms in any grade of postoperative complications at Day 30 or Day 90. Prespecified analyses did show trends favoring SIM for 2-year disease-free and overall survival, but these differences were not statistically significant, and follow-up continues.
The authors note that patients on both arms had lower-than-expected rates of postoperative ileus, which may highlight the importance of early feeding and consistent perioperative nutrition support.
(Hamilton-Reeves JM, JAMA Netw Open 2026)
To all SWOG members who contributed to the work described in these publications, thank you!
As we put the finishing touches on SWOG’s application for renewal of NCI support for our NCORP Research Base, these recently published results in cancer control and cancer prevention strengthen our argument for continued robust funding. We expect to soon have primary results in cancer care delivery to present as well. Stay tuned.
